A high resolution gas chromatographic/mass spectrometric method for the determination of N-0923 in human and monkey plasma.
A method that combines gas chromatography and mass spectrometry (GC/MS) for the determination of N-0923 in human and monkey plasma is detailed. This novel drug holds promise for the treatment of Parkinson's disease. Clinical use of N-0923 will result both in low peak plasma concentrations and in a short half-life; consequently, a highly sensitive method will be required. Previous methods using high-performance liquid chromatography with electrochemical detection have given reliable data in high dose studies in animals to 0.3-1.0 ng/mL in plasma but are not considered adequate for studies at clinical levels in humans. The data in this paper will show that GC/MS can offer a new direction in the determination of N-0923 in human and monkey samples, with reliable data to 25 pg/mL in plasma. This method is presented as a novel approach to the determination of N-0923, and as a starting point for further development.